Abstract | RATIONALE: MATERIALS AND METHOD: Fifty-nine patients hospitalized for first-episode DSM-IV schizophrenic disorder participated in this randomized double-blind study. Reboxetine (4 mg/day; 31 patients) or placebo (29 patients) was coadministered with olanzapine (10 mg/day) for 6 weeks. Analysis was by intention-to-treat. RESULTS: Nine patients in each group prematurely discontinued the trial. Olanzapine/ reboxetine-treated patients showed a significantly lower increase in body weight (mean = 3.31 kg, SD = 2.73) than their olanzapine/placebo-treated counterparts (mean = 4.91 kg, SD = 2.45). Significantly fewer olanzapine/ reboxetine-treated patients gained at least 7% of their initial weight, the cutoff for clinically significant weight gain (6 [19.4%] of 31 patients vs 13 [46.4%] of 28 patients). Seven (22.6%) olanzapine/ reboxetine-treated patients compared to only one patient (3.6%) in the olanzapine/placebo group revealed no weight change or even modest weight loss. Appetite increase was significantly lower in the olanzapine/ reboxetine than olanzapine/placebo group and was correlated with attenuation of weight gain. Reboxetine addition was safe and well tolerated. CONCLUSIONS: The results confirm that coadministration of reboxetine promotes a clinically meaningful attenuation of olanzapine-induced weight gain in schizophrenia patients. If substantiated in long-term studies, along with behavioral management and diet counseling, reboxetine may have a clinical utility in controlling SGA-induced weight gain.
|
Authors | Michael Poyurovsky, Camil Fuchs, Artashez Pashinian, Aya Levi, Sarit Faragian, Rachel Maayan, Irit Gil-Ad |
Journal | Psychopharmacology
(Psychopharmacology (Berl))
Vol. 192
Issue 3
Pg. 441-8
(Jun 2007)
ISSN: 0033-3158 [Print] Germany |
PMID | 17310385
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Antipsychotic Agents
- Morpholines
- Benzodiazepines
- Reboxetine
- Olanzapine
|
Topics |
- Adrenergic Uptake Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Adult
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Appetite
(drug effects)
- Benzodiazepines
(adverse effects, therapeutic use)
- Body Mass Index
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Morpholines
(adverse effects, pharmacology, therapeutic use)
- Olanzapine
- Reboxetine
- Schizophrenia
(drug therapy)
- Weight Gain
(drug effects)
|